Compare CQP & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CQP | INSM |
|---|---|---|
| Founded | 2003 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0B | 30.1B |
| IPO Year | 2006 | 2000 |
| Metric | CQP | INSM |
|---|---|---|
| Price | $66.59 | $133.66 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 24 |
| Target Price | $60.43 | ★ $201.17 |
| AVG Volume (30 Days) | 72.3K | ★ 1.6M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $10,758,000,000.00 | N/A |
| Revenue This Year | $6.35 | $182.31 |
| Revenue Next Year | $1.27 | $65.19 |
| P/E Ratio | $956.64 | ★ N/A |
| Revenue Growth | ★ 23.60 | N/A |
| 52 Week Low | $49.53 | $63.81 |
| 52 Week High | $70.64 | $212.75 |
| Indicator | CQP | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 61.68 | 35.20 |
| Support Level | $51.48 | $101.55 |
| Resistance Level | $70.64 | $166.81 |
| Average True Range (ATR) | 1.77 | 4.58 |
| MACD | 0.48 | -1.41 |
| Stochastic Oscillator | 91.21 | 5.45 |
Cheniere Energy Partners is a liquified natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The profit generated through those activities is split with parent and operator Cheniere Energy.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.